前列地尔联合依达拉奉治疗脑梗死疗效观察

Observate the efficacy of alprostadil combined with edaravone treatment on infarction

目的 探讨前列地尔联合依达拉奉治疗脑梗死的临床疗效及可行性.方法 将78例脑梗死患者随机分为实验组和对照组,对照组给予复方丹参注射液、胞二磷胆碱注射液常规治疗,实验组在此基础上给予前列地尔和依达拉奉治疗.比较两组神经功能缺损评分（NDS）、日常生活能力量表（ADL）及临床治疗效果.结果 两组治疗前NDS和ADL评分比较差异无统计学意义（P＞0.05）,治疗14 d后两指标较治疗前均明显改善（P＜0.05）,但实验组两指标改善幅度明显大于对照组（P＜0.05）.实验组治疗14 d后总有效率为95.0％,远高于对照组的76.3％ （P ＜0.05）,观察组并发症3例,少于对照组的7例（P＜0.05）.结论 前列地尔联合依达拉奉治疗脑梗死疗效确切,能有效缓解神经功能缺损程度,改善日常生活能力.

Objective To investigate the clinical efficacy and feasibility of alprostaudil and edaravone on cerebral infarction.Methods Seventy-eight cases of cerebral infarction were randomly divided into experimental group and control group.The patients of control group were treated with compound Danshen injection and citicoline injection conventional therapy.On this basis,the patients of experimental group were given alprostadil and edaravone.Then,the neurological deficit score（NDS）,ADL and clinical effect of the two groups were compared.Results Before treatment,the NDS and ADL scores of the two groups had no significant difference （P ＞ 0.05）,after 14 days of treatment,the indicators of two groups significantly improved （P ＜ 0.05）,but two indicators of magnitude improvement in the experimental group patients were significantly greater than the control group （P ＜ 0.05）.After 14 days of treatment,the total effective rate of the experimental group was 95.0％,it was far higher than the control group（76.3％） （P ＜ 0.05）.The experimental group had 3 cases of patients with complications,less than that in the control group（7 cases） （P ＜ 0.05）.Conclusions Alprostadil combine with edaravone has exact clinical efficacy on cerebral infarction.It can effectively alleviate the degree of neurological deficit and improve the ability of daily lives.